News and Announcements
Biotech Head, Leslie Chong Has Described Female Chiefs as “Unicorns”
- Published March 06, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Leslie Chong, Chief Executive of Australian-listed drug developer, Imugene, has spoken out about the idea of the glass ceiling as she believes there are plenty of capable women out there but for “whatever reason” men hold most CEO positions in the science and tech industry.
KEY TAKEAWAYS:
- Ms Chong is hoping she can reverse this trend as she helps her company break new ground in cancer drugs.
– Ms Chong has developed in this sector over 19 years, with hopes to lead the way in immo-oncology treatments and her quest is personal as her father died from gastric cancer.
– “What turned into a purely-financial itch, or means to get by, has turned into a passion”.
- Imugene’s work is centred around the HER 2 receptor which is present in about 20 per cent of gastric and breast cancers.
- The Company is developing a B-cell vaccine designed to stimulate a patient’s own immune system to produce antibodies to repeatedly attack the cancer.
“When I have to present to a large audience, I can’t help but say to the audience that ‘I’m the only women presenting today, you need to ask yourself why’,” she said. “That is important to me. I understand what I may represent for the rest of the people. I’m not trying to make myself a martyr but I do think it’s harder and I do have to be better — that could be self-driven but it could also be socially driven as well.
“On a daily basis I wake up and think, I’m a woman CEO of a biotech company … I’m humbled by it and feel I have to work harder because of that, because I’m representing here, in a lot of ways.”
“Imugene was in that niche area, where they are taking good technology and trying to put that in the forefront of a biotech development company.”
Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
